[{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATH-399A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals"},{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HL192","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"NurrOn Pharmaceuticals \/ NurrOn Pharmaceuticals"},{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NurrOn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NurrOn Pharmaceuticals \/ Hanall Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NurrOn Pharmaceuticals \/ Hanall Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by NurrOn Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 25, 2024

                          Lead Product(s) : HL192

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : Hanall Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 18, 2023

                          Lead Product(s) : ATH-399A

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Hanall Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 25, 2023

                          Lead Product(s) : ATH-399A

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Hanall Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank